IL7 and neoplasm: To assess the proliferative capacity of IL-7-CAR-T cells within the tumor microenvironment, we injected 2.5 × 106 cells (NT, CAR-T, or IL-7-CAR-T) into pre-established tumor sites using intratumoral injection.